Schering-Plough Ord Shs: All Recent News

• All recent news
• Earnings news

FDA OKs Abilify for autism-linked irritability 11/20/2009

PRINCETON, N.J. (AP) - The U.S. Food and Drug Administration has approved top-selling Abilify as a treatment for autism-related irritability in children from the ages of 6 to 17, drug maker Bristol-Myers Squibb Co. said Friday. Associated Press

Moody's gives negative view on pharma credit 11/19/2009

NEW YORK (AP) - Moody's Investors Service issued a negative opinion on the pharmaceutical industry Thursday, saying drugmaker credit ratings will be under pressure until early 2012 because they won't be able to fully replace revenue from best-sellers that go off-patent. Associated Press

InterMune shares fall on change in hepatitis study 11/17/2009

NEW YORK (AP) - Shares of InterMune Inc. fell Tuesday after the biotechnology company said it would discontinue a high-dose of its experimental Hepatitis C treatment in a study because of potential liver damage. Associated Press

Financial ETFs for Playing M&A Wave 11/16/2009

Four ETFs offer a range of exposure to the giant investment banks. At TheStreet.com

Study raises new questions about Merck pill Zetia 11/16/2009

ORLANDO, Fla. (AP) - A new study raises fresh concerns about Zetia and its cousin, Vytorin — drugs still taken by millions of Americans to lower cholesterol, despite questions raised last year about how well they work. Associated Press

Another Vytorin Mess For Merck 11/15/2009

A new study, though flawed, inflicts more damage on the company's Zetia and Vytorin cholesterol pills. At Forbes

Merck, now No. 2 drugmaker, set for future buys 11/4/2009

TRENTON, N.J. (AP) - The new Merck & Co. has become the world's second-biggest drugmaker overnight with a huge acquisition, but it still has a fat wallet and plans more wheeling and dealing. Associated Press

Fitch lowers Merck ratings after Schering purchase 11/4/2009

NEW YORK (AP) - A day after drugmaker Merck & Co. completed its $41.1 billion purchase of rival Schering-Plough Corp., Fitch Ratings Service on Wednesday cut its ratings on Merck and upgraded Schering-Plough. Associated Press

A Little Distracted, Are You, Merck? 11/3/2009

The FDA rejects its latest application. At Motley Fool

Merck to complete $41B purchase of Schering-Plough 11/3/2009

WHITEHOUSE STATION, N.J. (AP) - Merck & Co. is set to complete its $41 billion acquisition of Schering-Plough Corp. later Tuesday, creating the world's second-largest drugmaker, behind Pfizer Inc. Associated Press

Merck, Schering-Plough to complete merger Tuesday 11/3/2009

BOSTON (MarketWatch) -- Merck & Co. and Schering-Plough Corp. said they will complete their $41 billion merger after the market's close on Tuesday. As a result, Schering-Plough's stock will cease trading later Tuesday. The combined company will be known as Merck, with shares trading under the symbol MRK on the New York Stock Exchange. Under the terms of the deal, Schering-Plough shareholders will receive approximately 0.58 shares of the newly-combined company's stock and $10.50 in cash for each Schering-Plough share. Each Merck share will automatically convert to one share of the new... At MarketWatch

Merck and Schering-Plough to Complete Merger Today 11/3/2009

Merck & Co., Inc. (NYSE: MRK) and Schering-Plough Corporation (NYSE: SGP) today announcedthat they will complete their merger shortly after 4:00PM ET today. The companies will begin combined... Business Wire

J&J To Cut 7% of Workforce 11/3/2009

... At Barron's

$ A Tutorial in Defensive Investing 11/3/2009

... At Barron's

FDA won't accept Merck's application for new drug 11/2/2009

TRENTON, N.J. (AP) - U.S. regulators have refused to accept drugmaker Merck & Co.'s application for a new, combination cholesterol pill that includes rival Pfizer's Lipitor, the world's top-selling drug. Associated Press

More News

Market Report

News by Symbol

Today's Investing Articles

Breaking News

News by Topic

News by Industry

MSNBC News

MSN Money

Search MSN Money

Message Boards

Site Status